United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$229.72 USD
-13.55 (-5.57%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $229.22 -0.50 (-0.22%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum B VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 1 - 20 ( 581 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4/FY23: Rounding Out the Year of Tyvaso DPI w/ Another Record Revenue Quarter
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Near-Term Growth With TETON Program Broadening Upside; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2024 Outlook on Covered Companies Takeaways from Annual SF Biotech Meetings
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Federal Circuit Affirms ''793 PTAB Decision; Tyvaso DPI''s Dominance to Persist
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Optimized Entry and Exit Levels for UTHR 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Defines Near-Term Growth With TETON Program As Next Chapter; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A